The Money Players in biotech are back
ImClone Ex-CEO Waksal Is Back I’m following Kadmon Pharmaceuticals for reasons that are almost too obvious to state. Waksal and his cadre of biotech men are considered in my estimation as the money players of the industry. They successfully raise the funds to develop the drugs they can market to the world, handsomely profiting from … Read more
Lilly’s New R&D Strategy
Biotechnology was the biggest industry for venture funding in the first half of this year, with investors pouring $2.1 billion into 243 companies, according to the National Venture Capital Association, which tracks 17 categories. Industrial and energy was second at $1.94 billion.
Venture fundraising is showing signs of picking up again after dropping 56 percent in the second quarter from a year earlier. Institutional Venture Partners and Founders Fund, as well as smaller firms such as Floodgate Fund and Felicis Ventures, completed funds in the third quarter.
Lilly’s strategy is “another way in which companies can spread research and development dollars to more emerging opportunities without necessarily having to buy a company or make a direct investment,” Tony Butler, an analyst with Barclays Capital in New York, said yesterday in a telephone interview.
Still, it won’t fill the revenue gap the company faces in the next few years, he said. Any new drugs arising from the partnerships would come “way beyond 2015.”
Methods of a Venture Capitalist: Part II (Valuation)
Building upon Part I’s edition of MoVC, Part II discusses the valuation aspect of a start-up once a VC decides to pull the trigger and invest. Here’s the best way to value your startup (article from Venturebeat)
Methods of a Venture Capitalist: Part I
The VC game is considered a black art for a particular reason. It is on all accounts an inexact science in valuation that requires a balance of knowledge and business instinct. The nature of the deal also makes for a unique transaction. We understand the concomitant incompatibility between entrepreneur and venture capitalist and find the … Read more
Patience is a [lucrative] virtue
3Par Venture Backers Reap $560 Million by Hanging On Patience paid off for the venture capitalists who backed data-storage supplier 3Par Inc. 3Par’s earliest and biggest venture investors, Menlo Ventures, Worldview Technology Partners and Mayfield Fund reaped a combined $560 million windfall by holding onto shares acquired near the time of the company’s initial public … Read more
Royal Phillips foresee growth in healthcare sub-sectors
“There’s a lot of space in those three categories of cardiology, oncology and women’s health, not necessarily completely isolated to one company,” he said. “There are plenty of opportunities for us to explore and that will continue to give us good growth.”
‘Super Angels’ fly in to aid Start-Ups
While their funds tend to be small, super angels have had an outsize impact on Silicon Valley. As many traditional venture capitalists retreated after the tech bust last decade, super angels filled the gap, investing small amounts of $25,000 to $1 million in dozens of new start-ups such as Facebook Inc., Mint.com and Zynga Game Network Inc. Super angels also work with established venture capitalists to bring them new deals.
Methods of a Venture Capitalist: Intro
We’ve read the quotation from Joyce’s Stephen Dedalus before. Heck we’ve even had an experience or two that makes his exhortation universally intimate: “To live, to err, to fall, to triumph, to recreate life out of life!” For no other profession does the power of Stephen’s words ring so profoundly true as in the Venture … Read more
Tiger Global Said to Invest in LinkedIn at $2 Billion Valuation
Tiger Global Said to Invest in LinkedIn at $2 Billion Valuation
